|
" Adjuvant Chemotherapy of Breast Cancer : "
edited by Hans-Jörg Senn.
Document Type
|
:
|
BL
|
Record Number
|
:
|
723549
|
Doc. No
|
:
|
b543264
|
Main Entry
|
:
|
edited by Hans-Jörg Senn.
|
Title & Author
|
:
|
Adjuvant Chemotherapy of Breast Cancer : : Papers Presented at the 2nd International Conference on Adjuvant Chemotherapy of Breast Cancer, Kantonsspital St. Gallen, Switzerland, March 1-3, 1984\ edited by Hans-Jörg Senn.
|
Publication Statement
|
:
|
Berlin, Heidelberg: Springer Berlin Heidelberg, 1984
|
Series Statement
|
:
|
Recent results in cancer research, 96.
|
ISBN
|
:
|
3642823572
|
|
:
|
: 3642823599
|
|
:
|
: 9783642823572
|
|
:
|
: 9783642823596
|
Contents
|
:
|
Scientific Basis of Adjuvant Chemotherapy in Breast Cancer --;The Preclinical Scientific Basis for Adjuvant Chemotherapy in Breast Cancer --;The Clinical-Scientific Basis of Adjuvant Chemotherapy in Breast Cancer --;Molecular and Cellular Mechanisms Underlying Ineffective Cancer Chemotherapy --;Impact of Early Detection of Breast Cancer on Adjuvant Chemotherapy --;Contribution of Prognostic Factors to Adjuvant Chemotherapy in Breast Cancer --;Review: Scientific Basis of Adjuvant Chemotherapy in Breast Cancer --;Clinical Results I: Experience of Randomized Trials with Surgical Controls --;Scandinavian Trials with a Short Postoperative Course Versus a 12-Cycle Course --;A Brief Overview of Findings from NSABP Trials of Adjuvant Therapy --;CMF Adjuvant Programs at the Milan Cancer Institute --;A Controlled Trial of Adjuvant Chemotherapy with Melphal-an Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer --;Adjuvant Chemoimmunotherapy with LMF + BCG in Node-Negative and Node-Positive Breast Cancer: 8 Year Results --;Ludwig Breast Cancer Trial LBCS III: Chemo-and Endocrine Adjuvant Treatment in Postmenopausal Patients --;Postmenopausal Node-Positive Comparison of Observation with CMFP and CMFP + Tamoxifen Adjuvant Therapy An Eastern Cooperative Oncology Group Trial --;Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group's Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal Patients --;Clinical Results II: Experience of Non-Randomized Trials with Historical or Mached Surgical Controls --;FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update --;Current Results of the University of Arizona Adjuvant Breast Cancer Trials (1974-1984) --;Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer --;The Use of a Natural History Data Base to Compare Outcome Among Several Trials of Adjuvant Chemotherapy for Stage II Breast Cancer --;Clinical Results III: Experience of Randomized Trials Without Surgical Controls --;Adjuvant Systemic Therapy in Postoperative Node-Positive Patients with Breast Carcinoma: The CALGB Trial and the ECOG Premenopausal Trial --;Adjuvant Therapy of Breast Cancer: A Southwest Oncology Group Experience --;Short- or Long-term Chemotherapy for Node-Positive Breast Cancer: LMF 6 Versus 18 Cycles. SAKK Study 27/26 --;Adjuvant Programs for Postmenopausal Women with Node-Positive Breast Cancer: Preliminary Analysis of 5-Year Results --;Review: Experience of Randomized Trials Without Surgical Controls --;Remaining Problems of Adjuvant Chemotherapy in Breast Cancer --;Second Malignant Neoplasms in Operable Carcinoma of the Breast --;Tamoxifen and Combination Chemotherapy as Adjuvant Treatment in Postmenopausal Women with Breast Cancer --;Ludwig Breast Cancer Trials LBCS III and IV: Adjuvant Endocrine Treatment in Postmenopausal Patients --;Problems of Combined Adjuvant Radiochemotherapy --;The Present Dilemma of Adjuvant Chemotherapy: Acceptance and Risks Versus Benefits --;Are Current Worldwide Studies Going to Answer the Important Questions Remaining in Adjuvant Chemotherapy of Breast Cancer? --;Closing Remarks and Outlook --;Closing Remarks and Outlook.
|
Abstract
|
:
|
Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago.
|
Subject
|
:
|
Gynecology.
|
Subject
|
:
|
Medicine.
|
Subject
|
:
|
Toxicology.
|
LC Classification
|
:
|
RC261.E358 1984
|
Added Entry
|
:
|
Hans-Jörg Senn
|
| |